Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Pentaisomaltose, an Alternative to DMSO. Engraftment of Cryopreserved Human CD34+ Cells in Immunodeficient NSG Mice

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina - one year follow-up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. COMPARISON OF HUMAN ADIPOSE-DERIVED STEM CELLS AND BONE MARROW-DERIVED STEM CELLS IN A MYOCARDIAL INFARCTION MODEL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Retinal progenitor cell xenografts to the pig retina: immunological reactions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Only minor stem cell mobilization in head and neck irradiated patients treated with hyperbaric oxygen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. xxx

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Hematopoietic stem cell transplantation often involves the cryopreservation of stem cell products. Currently, the standard cryoprotective agent (CPA) is dimethyl sulfoxide (DMSO), which is known to cause concentration-related toxicity and side effects when administered to patients. Based on promising in vitro data from our previous study using pentaisomaltose (a 1 kDa subfraction of Dextran 1) as an alternative to DMSO for cryopreservation of hematopoietic progenitor cells (HPCs) from apheresis products, we proceeded to a preclinical model and compared the two CPAs with respect to engraftment of human hematopoietic stem and progenitor cells (HSPCs) in the immunodeficient NSG mouse model. Human HPCs from apheresis products were cryopreserved with either pentaisomaltose or DMSO, and the following outcomes were measured: (1) the post-thaw recovery of cryopreserved cells and clonogenic potential of CD34+ cells and (2) hematopoietic engraftment in NSG mice. We found that recovery and colony-forming cells data were comparable between pentaisomaltose and DMSO. The engraftment data revealed comparable human CD45+ levels in peripheral blood at 8 weeks and bone marrow at 16 weeks post transplantation. Additionally, the frequencies of CD34+CD38low/negative and myeloid/lymphoid cells in the bone marrow were comparable. We here demonstrated that long-term engrafting HSPCs were well preserved in pentaisomaltose and comparable to cells cryopreserved with DMSO. Although a clinical trial is necessary to translate these results into human use, the present data represent an important step toward the replacement of DMSO with a non-toxic alternative.

OriginalsprogEngelsk
TidsskriftCell Transplantation
Vol/bind27
Udgave nummer9
Sider (fra-til)1407-1412
Antal sider6
ISSN0963-6897
DOI
StatusUdgivet - sep. 2018

ID: 55351864